Results 201 to 210 of about 95,030 (266)

Assessment of multimodal CEST, perfusion and diffusion MRI for predicting clinical outcome of patients with diffuse glioma following surgery at baseline before radiotherapy. [PDF]

Cancer Imaging
von Knebel Doeberitz N, Menshchikov P, Kroh F, König L, Graß S, Bauspieß C, Boyd PS, Regnery S, Zeyen T, Schaumann S, Floca R, Hasson D, Scherer M, Bendszus M, Wick W, Debus J, Bachert P, Ladd ME, Schlemmer HP, Korzowski A, Paech D.   +20 more
europepmc   +1 more source

Non‐Invasive Estimation of Systemic Drug Exposure Using Exhaled Breath Metabolomics in Humans: A Translational Proof‐of‐Concept Study

Clinical Pharmacology &Therapeutics, EarlyView.
Accurate assessment of systemic drug exposure in humans remains challenging, as conventional approaches rely on intermittent blood sampling and laboratory‐based assays that are invasive and provide limited temporal resolution. Exhaled breath contains volatile and semi‐volatile compounds arising from drug metabolism and downstream biological processes ...
Kai Fricke, Diego M. Baur, Kapil Dev Singh, Felix Schmidt, Kathrin Müsch, Noriane A. Sievi, Marco Di Donato, Anton Schmick, Jonas Herth, Silvia Ulrich, Pablo Sinues, Marian Galovic, Malcolm Kohler   +12 more
wiley   +1 more source

Multiple linear regression modeling with values below a lower limit of quantification - a statistical method comparison. [PDF]

BMC Med Res Methodol
Hafermann L, Yokota I, Kalski L, Wolfarth B, Herrmann C.   +4 more
europepmc   +1 more source

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

Clinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N. Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert   +8 more
wiley   +1 more source

Regression analysis of interval-censored competing risks data with missing causes of failure: A direct likelihood approach. [PDF]

Stat Methods Med Res
Lou Y, Ma Y, Xiang L, Sun J.
europepmc   +1 more source

Time‐Dependent Bias and Prognostic Confounding in Exposure–Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure–response (E–R) analyses of sunitinib in metastatic renal cell carcinoma (mRCC) have supported concentration‐guided dose escalation. However, such analyses may be biased when exposure metrics incorporate post‐baseline dose modifications, time‐varying apparent clearance, or baseline factors that influence both pharmacokinetics and clinical ...
Han Liu, Lena E. Friberg
wiley   +1 more source

Mapping Metastatic Spread in Uterine Sarcoma: A Population-Based Analysis of First Metastatic Patterns and Outcomes. [PDF]

Cancers (Basel)
Gennari P, Ignatov A.
europepmc   +1 more source

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer. [PDF]

Front Endocrinol (Lausanne)
Watanabe M, Eguchi J, Takamoto A, Wada J.   +3 more
europepmc   +1 more source

Time-Dependent Predictive Accuracy Metrics in the Context of Interval Censoring and Competing Risks. [PDF]

Biom J
Yang Z, Rizopoulos D, Newcomb LF, Erler NS.   +3 more
europepmc   +1 more source

Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency. [PDF]

Brain Commun
Hirano M, Garone C, Haas R, Paradas C, Scaglia F, Rebollo Mesa I, Chiang C, Colson AO, VanMeter S, Domínguez-González C.   +9 more
europepmc   +1 more source